Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically and biopsy confirmed non-neoplasia epithelial disorders of skin and mucosa of vulva.~* Patient must have a score of 5 or greater in the itching score table before treatment and the itching must last at least 6 months.~Exclusion Criteria:~* Patients with vulvovaginal or other gynecological trauma, acute inflammatory diseases and other acute illness~* Patients have been treated with any kind of topical therapy at the vulva within 12 weeks prior to participation in the study~* Patients with other serious diseases (e.g. liver or kidney diseases) that need immediate treatment~* Patients with atypical vulvar hyperplasia or vulvar cancer confirmed by biopsy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- treatment group (Type: EXPERIMENTAL): Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department.

Based on this trial design, predict the completion outcome and termination type (if applicable).